U.K. PSE Rx only?
This article was originally published in The Tan Sheet
Executive Summary
The Proprietary Association of Great Britain says the U.K. Medicine and Healthcare products Regulatory Agency should not make pseudoephedrine prescription-only in an April 25 release. In March MHRA proposed Rx-only status for PSE- and ephedrine-containing OTCs to prevent the manufacture of methamphetamine (1"The Tan Sheet" March 12, 2007, p. 4). "We urge the government not to take disproportionate measures to control pseudoephedrine that would affect legitimate usage and consumer needs," PAGB says. The group encourages PSE restrictions similar to U.S. measures such as sales limits and behind-the-counter or locked cabinet storage (2"The Tan Sheet" March 6, 2006, p. 5)...
You may also be interested in...
U.K. Proposes Prescription-Only Status For Pseudoephedrine Products
The U.K. Medicines and Healthcare products Regulatory Agency is proposing prescription status for pseudoephedrine- and ephedrine-containing drugs in order to prevent the illegal manufacture of methamphetamine
Pseudoephedrine Will Be Behind The Counter Across The Country By October
Retailers will have to be prepared to enforce monthly gram purchase limits on pseudoephedrine products by mid-April, once meth control provisions of the Patriot Act reauthorization bill go into effect
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.